EXEL SP | EXEL Message Board Posts

EXEL   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  21659 of 22110  at  3/13/2019 8:20:11 PM  by

erniewerner


 In response to msg 21655 by  hbomb57108
view thread

Re: EXEL SP

"I thought KN-426 would be great, but damn .53 HR! I would guess that if you ran this trial 100 times this .53 HR would be in top 5% upper tier of best possible outcomes. Yeah, I think KN-426 got some favorable statistical randomness. I would be shocked if this HR improved on subsequent analysis..."
 
First, I doubt that there will be continued follow up for more mature data.  They already hit on all the primary and secondary endpoints, there is nothing left to prove.  Hypothetically, if there were follow up, and HR=.53 is a favorable outlier, you would have two competing forces, you may get a reversion to the norm pushing toward a less spectacular outcome, but remember checkpoint survival vs TKI monotherapy improves with time.  That fat tail on the right side of the survival curve pads the HR advantage.  No matter how you cut it, it is a very tough act to follow.  
 
Keep in mind though, until something better comes along, Cabo will still be the preferred 2L treatment for patients who progress on Pembro/Ax.   
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 4     Views: 373
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
21660 Re: EXEL SP JoeFlow 5 3/13/2019 9:14:56 PM


About Us    Contact Us    Follow Us on Twitter    Members Directory    Help Center    Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
2003-2018 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...